BB 2827

Drug Profile

BB 2827

Latest Information Update: 09 Apr 2009

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator British Biotech
  • Developer British Biotech; Merck Serono
  • Class Antirheumatics
  • Mechanism of Action Matrix metalloproteinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Periodontal disorders; Rheumatoid arthritis

Most Recent Events

  • 27 Jul 2001 Discontinued-I for Rheumatoid arthritis in Europe (PO)
  • 26 Jun 2001 Investigation in Periodontal disorders in Europe (PO)
  • 31 Oct 2000 Serono has an option to obtain exclusive rights to BB 2827
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top